03.12.2021 • News

Barentz Acquires India’s Gangwal Chemicals

Globally active life science ingredients distributor Barentz International is acquiring an undisclosed majority stake in the distribution activities of India’s Gangwal Chemicals. The Mumbai-based company is a high-end distributor and specialty solutions provider that focuses on pharmaceuticals with a strong presence in the pharmaceutical, nutraceutical, personal care and cosmetics ingredients segments. Additionally, it has a strong position in high-end and niche specialty excipients.

The deal, for which no selling price or completion date has been announced, is subject to customary closing conditions. Anil Jain, Gangwal,’s founder, will continue to lead the company.

Barentz said the acquisition of the company that is “growing significantly” in the distribution of specialty ingredients for nutraceuticals and cosmetics represents an important step in its strategy to become a leading global specialty pharmaceutical and nutraceutical active ingredient distributor.

(c) Pixabay
(c) Pixabay

The Dutch distributor said the deal will deepen its footprint in the pharma excipient distribution market as well as widening its geographic exposure in the fast-growing Asia-Pacific region. Gangwal provides excellent scope for further growth opportunities, organically and through acquisition in India and Asia-Pacific, it added.

Hidde van der Wal, CEO of Barentz, commented that his company has been keen to enter the Indian market for a long time, and in Gangwal has found the right partner. Van der Wal told CMI earlier this year that Barentz has a “selective but active” buy-and-build strategy to create global leadership in the life science distribution market, which allows it to strengthen its existing geographical regions and develop new regions.

Author: Dede Williams, Freelance Journalist

Interview

The UK Chemical Supply Chain
Trade and Competitiveness

The UK Chemical Supply Chain

The CBA, led by CEO Tim Doggett, is steering the UK chemical supply chain through trade uncertainty, sustainability pressures and logistics challenges, as he explains in this interview with CHEManager.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.